Literature DB >> 11368912

Cloning of dog heart PDE1A - a first detailed characterization at the molecular level in this species.

J C Clapham1, A F Wilderspin.   

Abstract

The dog, as a model for cardiovascular function, has been widely used in the pharmacological analysis of PDE inhibitors, particularly those thought to target the heart. However biochemical analyses of dog heart PDE have been largely performed on mixed enzyme populations, sequence information is lacking and no PDE from dog heart has been cloned. We have characterized a completely purified PDE1 enzyme from dog heart using dye-affinity, Mono-Q and calmodulin-affinity chromatography. The enzyme was stimulated 3-4-fold by calmodulin ([S]=0.5 microM) and, in the absence of calmodulin, exhibited biphasic kinetics with a low K(m) of 1.2 microM and 0.53 microM for cAMP and cGMP, with respective V(max) values of 283 and 146 nmoles min(-1) mg(-1). Internal peptides from this enzyme were used to design degenerate PCR primers. Subsequent 3'-RACE, 5'-RACE and high fidelity PCR were then used to produce a full length gene identified as PDE1A1 by sequence identity to human and bovine sequences. Northern analysis using the dog heart cDNA as a probe suggested the presence of an additional form of PDE1, in heart only, separate from the PDE1A group which was present in both heart and skeletal muscle. Multiple forms of human PDE1A are known to exist and PDE1B is present in human heart muscle. The findings here extend the PDE1 data to the dog and contribute to our understanding of the molecular biology of PDE1A in this species.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368912     DOI: 10.1016/s0378-1119(01)00413-9

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

Review 1.  Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.

Authors:  Chen Yan; Clint L Miller; Jun-ichi Abe
Journal:  Circ Res       Date:  2007-03-02       Impact factor: 17.367

Review 2.  Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

Authors:  Clint L Miller; Chen Yan
Journal:  J Cardiovasc Transl Res       Date:  2010-07-15       Impact factor: 4.132

3.  Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.

Authors:  Clint L Miller; Masayoshi Oikawa; Yujun Cai; Andrew P Wojtovich; David J Nagel; Xiangbin Xu; Haodong Xu; Vince Florio; Sergei D Rybalkin; Joseph A Beavo; Yiu-Fai Chen; Jian-Dong Li; Burns C Blaxall; Jun-ichi Abe; Chen Yan
Journal:  Circ Res       Date:  2009-09-24       Impact factor: 17.367

Review 4.  Cyclic nucleotide phosphodiesterases in pancreatic islets.

Authors:  N J Pyne; B L Furman
Journal:  Diabetologia       Date:  2003-08-07       Impact factor: 10.122

Review 5.  Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

Authors:  Arun Samidurai; Lei Xi; Anindita Das; Audra N Iness; Navin G Vigneshwar; Pin-Lan Li; Dinender K Singla; Sakthivel Muniyan; Surinder K Batra; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2021-04-22       Impact factor: 13.400

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.